Mitogen-activated protein kinase

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Retrieved on: 
Wednesday, December 8, 2021
Patent Prosecution Highway, Patent, Population, Toxicity, Technology, Radiation, Quality of life, PI3K, Skin, Patient, Breast cancer, James A. Schlipmann Melanoma Cancer Foundation, Cancer, TEL, Growth factor, RD, Mitogen-activated protein kinase, Intellectual property, Clinical trial, EGFR, Compliance, Cell, Pharmaceutical industry

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.

Key Points: 
  • Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
  • Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program.
  • Lutris also has additional provisional patents for dosing and novel indications.
  • Additional information on the patent portfolio can be found on "Intellectual Property" section of the Lutris website at: www.lutris-pharma.com/intellectual-property .

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Retrieved on: 
Wednesday, December 8, 2021
Patent Prosecution Highway, Patent, Population, Toxicity, Technology, Radiation, Quality of life, PI3K, Skin, Patient, Breast cancer, James A. Schlipmann Melanoma Cancer Foundation, Cancer, TEL, Growth factor, RD, Mitogen-activated protein kinase, Intellectual property, Clinical trial, EGFR, Compliance, Cell, Pharmaceutical industry

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.

Key Points: 
  • Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
  • Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program.
  • Lutris also has additional provisional patents for dosing and novel indications.
  • Additional information on the patent portfolio can be found on "Intellectual Property" section of the Lutris website at: www.lutris-pharma.com/intellectual-property .

MAP Kinase Kinase 1 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 30, 2021
Health, Biotechnology, Royal commission, Patient, RAS, News, Discovery, Pancreatic cancer, Ovarian cancer, Cancer, Protein, Mitogen-activated protein kinase, Lung cancer, MEK, MAPK, MEK2, EGFR, LGG, Clinical trial, RAF, Food, Disease, Therapy, NF1, Melanoma, Endometrial cancer, Colorectal cancer, Orphan drug, Fast Track, MAP, Selumetinib, III, FDA, European Commission, MEK1, Inhibitor, II, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Growth, Fertilizer, Pharmaceutical industry

The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "MAP kinase kinase 1 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MAP kinase kinase 1 inhibitors R&D.
  • The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.

BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

Retrieved on: 
Tuesday, July 27, 2021
Enzymes, Branches of biology, Signal transduction, Mitogen-activated protein kinase, Ras GTPase, PTPN11, Programmed cell death protein 1, Nivolumab, IRS1, MAPK/ERK pathway

Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.

Key Points: 
  • Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.
  • Both BridgeBio and Bristol Myers Squibb will share the cost of clinical development activities for the combination trial.
  • SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival.
  • Combination of anti-PD-1 treatment with BBP-398, and other targeted therapies, could be promising for patients with KRAS mutations.

Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib

Retrieved on: 
Tuesday, February 23, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Branches of biology, Signal transduction, Biology, Cell biology, MAPK/ERK pathway, Mitogen-activated protein kinase, Small molecule, Pimasertib, Day One Biopharmaceuticals

Pimasertib and MSC2015103B are oral, highly-selective small molecule allosteric inhibitors of MEK 1/2, a key enzyme in the MAPK signaling pathway.

Key Points: 
  • Pimasertib and MSC2015103B are oral, highly-selective small molecule allosteric inhibitors of MEK 1/2, a key enzyme in the MAPK signaling pathway.
  • Pimasertib has been studied in more than 10 Phase 1/2 clinical trials in approximately 900 patients with various tumor types.
  • The Companys pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, highly selective small molecule inhibitor of MEK.
  • 1Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005380/en/

Mitogen Activated Protein Kinase Kinase 2 inhibitors Pipeline Insight 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021
Health, Pharmaceutical, Enzymes, Protein kinases, Protein kinase, Mitogen-activated protein kinase, MAP3K19, Raf kinase inhibitor protein

The "Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mitogen Activated Protein Kinase Kinase 2 inhibitors pipeline landscape.
  • Mitogen Activated Protein Kinase Kinase 2 inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Mitogen Activated Protein Kinase Kinase 2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Mitogen Activated Protein Kinase Kinase 2 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient

Retrieved on: 
Wednesday, January 6, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Branches of biology, Enzymes, Signal transduction, Oncogenes, Protein kinases, Ras GTPase, Biology, Mitogen-activated protein kinase

With this approach, we hope to induce tumor regression in RAS/MAPK-driven cancers, while also blocking their main escape routes.

Key Points: 
  • With this approach, we hope to induce tumor regression in RAS/MAPK-driven cancers, while also blocking their main escape routes.
  • With both ERAS-601 and ERAS-007, we look forward to exploring multiple therapeutic combinations with Erascas other pipeline programs and with external partners agents.
  • Under the terms of the NiKang agreement, Erasca licensed exclusive, worldwide rights to ERAS-601 and all other SHP2 inhibitors developed by NiKang.
  • Under the terms of the Asana agreement, Erasca acquired exclusive, worldwide rights to ERAS-007 and all other ERK inhibitors developed by Asana.

Immuneering Completes Oversubscribed $62 Million Series B Financing

Retrieved on: 
Tuesday, January 5, 2021
Branches of biology, Signal transduction, Biology, Cell biology, MAPK/ERK pathway, Mitogen-activated protein kinase, Ras GTPase

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the completion of an oversubscribed $62 million Series B financing led by Cormorant Asset Management, with participation from Surveyor Capital (a Citadel company), Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed byBlackRock, Perceptive Advisors and LYFE Capital.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the completion of an oversubscribed $62 million Series B financing led by Cormorant Asset Management, with participation from Surveyor Capital (a Citadel company), Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed byBlackRock, Perceptive Advisors and LYFE Capital.
  • Immuneering will use proceeds from the financing to advance to clinical stage programs focused on targets in the RAS/MAPK pathway, a cellular signaling pathway commonly activated in many different tumor types and cancers.
  • Andrew Phillips of Cormorant Asset Management stated, "With new treatments urgently needed for patients who have tumors dependent on MAPK signaling, we are thrilled to lead this Series B financing and bring together a syndicate to support Immuneering at a pivotal stage in the companys growth.
  • Immuneering also has multiple additional preclinical programs in oncology, neuroscience and immuno-oncology.

xCures launches xACCESS - A new module in their AI-assisted clinical platform

Retrieved on: 
Tuesday, November 17, 2020
Health sciences, Health, Branches of biology, Clinical pharmacology, Clinical research, Drug discovery, Pharmaceutical industry, Animal virology, Bovine viral diarrhea, Clinical trial, Mitogen-activated protein kinase, Oncology

SAN FRANCISCO, Nov. 17, 2020 /PRNewswire/ -- Today, xCures Inc. is launching xACCESS - a new registration module for their AI-assisted clinical study platform.

Key Points: 
  • SAN FRANCISCO, Nov. 17, 2020 /PRNewswire/ -- Today, xCures Inc. is launching xACCESS - a new registration module for their AI-assisted clinical study platform.
  • The xCures platform uses a Master Observational Registry to efficiently run a wide variety of oncology studies and decentralized trials, prospectively generating real-world evidence.
  • "xACCESS is xCures' first patient-centric technology module, onboarding patients directly to our sponsored studies and partner programs," stated Mika Newton, xCures' CEO.
  • The xACCESS module will be used for all clinical studies and programs available on the xCures platform, including the recently announced Compassionate Use program for ulixertinib (BVD-523), currently enrolling patients with MAPK pathway aberrant cancer.

xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

Retrieved on: 
Monday, September 28, 2020
Enzymes, Signal transduction, Protein kinases, Extracellular signal-regulated kinases, Mitogen-activated protein kinase, Kinase, MAPK/ERK pathway, MAP kinase kinase kinase

This intermediate-sized expanded access program ( NCT04566393 ) is currently open and available for physicians interested in treating their patients.

Key Points: 
  • This intermediate-sized expanded access program ( NCT04566393 ) is currently open and available for physicians interested in treating their patients.
  • Patients can register and find more information at enroll.xcures.com/uli-eap or receive additional information via xCures patient advocacy partner Cancer Commons ( www.cancercommons.org ).
  • Ulixertinib is a first-in-class and best-in-class small-molecule inhibitor ofextracellular signal-regulated kinase (ERK)family kinases (ERK1 and ERK2) thatis being developedas a novel anti-cancer drug.
  • This Expanded Access program provides ulixertinib for compassionate use in advanced cancer patients with a MAPK pathway-altered solid tumor(s) who have exhausted available therapies.